We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

21 hedge funds and large institutions have $50.9M invested in Summit Therapeutics in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 1

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

67% more capital invested

Capital invested by funds: $30.5M → $50.9M (+$20.4M)

50% more funds holding

Funds holding: 14 → 21 (+7)

1.42% more ownership

Funds ownership: 4.35% → 5.77% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
21
Holders Change
+7
Holders Change %
+50%
% of All Funds
0.52%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
8
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
LPU
Lansdowne Partners (UK)
United Kingdom
+$8.64M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.89M
3
GPCM
Granite Point Capital Management
Massachusetts
+$1.62M
4
PC
Polar Capital
United Kingdom
+$1.3M
5
HCM
Highbridge Capital Management
New York
+$1.04M

Top Sellers

1
KCM
Knoll Capital Management
Florida
-$106K
2
Axa
Axa
France
-$50K
3
TRCT
Tower Research Capital (TRC)
New York
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPU
1
Lansdowne Partners (UK)
United Kingdom
$20M +$8.64M +666,666 +72%
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$10.1M +$67.9K +5,240 +0.7%
Axa
3
Axa
France
$3.55M -$50K -3,856 -1%
GPCM
4
Granite Point Capital Management
Massachusetts
$3.03M +$1.62M +125,000 +107%
SFM
5
Sphera Funds Management
Israel
$2.65M +$907K +70,000 +49%
First Eagle Investment Management
6
First Eagle Investment Management
New York
$2.19M – – –
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$1.83M +$1.89M +146,000 New
Renaissance Technologies
8
Renaissance Technologies
New York
$1.27M +$810K +62,500 +162%
PC
9
Polar Capital
United Kingdom
$1.25M +$1.3M +100,000 New
KCM
10
Knoll Capital Management
Florida
$1.15M -$106K -8,200 -8%
HCM
11
Highbridge Capital Management
New York
$1M +$1.04M +80,000 New
Millennium Management
12
Millennium Management
New York
$968K +$16.7K +1,291 +2%
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$628K +$648K +50,000 New
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$618K +$471K +36,356 +283%
Deutsche Bank
15
Deutsche Bank
Germany
$465K +$388K +29,930 +419%
UBS Group
16
UBS Group
Switzerland
$40K +$40.4K +3,117 New
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$31K – – –
State of Tennessee, Department of Treasury
18
State of Tennessee, Department of Treasury
Tennessee
$19K – – –
Citigroup
19
Citigroup
New York
$3K +$2.59K +200 New
Bank of Montreal
20
Bank of Montreal
Ontario, Canada
$3K +$3.37K +260 New
TRCT
21
Tower Research Capital (TRC)
New York
– -$3K -300 Closed
Bank of America
22
Bank of America
North Carolina
– +$65 +5 New

SMMT Hedge Fund Activity: Q3 2017 in Review

21 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2017, worth a combined $50.9M — up 67% from $30.5M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new SMMT positions and 1 closed out — a net gain of 7 holders — while 8 added to existing stakes and 2 trimmed.

The largest buyer was Lansdowne Partners (UK), adding an estimated $8.64M. The largest seller was Knoll Capital Management, cutting an estimated $106K.

  • 21 institutional investors held Summit Therapeutics (SMMT) as of Q3 2017, up from 14 in Q2 2017.
  • Funds reported $50.9M of Summit Therapeutics stock for Q3 2017, up 67% quarter-over-quarter.
  • 8 funds opened new Summit Therapeutics positions in Q3 2017 and 1 closed out, a net change of +7 holders.
  • The largest Summit Therapeutics buyer in Q3 2017 was Lansdowne Partners (UK), an estimated $8.64M added.
  • The largest Summit Therapeutics seller in Q3 2017 was Knoll Capital Management, an estimated $106K sold.

Based on aggregated 13F filings for Q3 2017.